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S188 Oral Presentationscomposed of mature, long-lived B and T-cells that do not need to be
regenerated by HSC.
Expansion of this work could enable efficient, safe transplantation
ofHSC that cannot causeGvH, resulting in a potential curative ther-
apy for almost any hematologic or immunologic disease.93
TIE21 ENDOTHELIAL CELLS MEDIATE HEMATOPOIETIC STEM CELL RE-
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Hematopoietic stem cells (HSCs) reside in anatomic association
with sinusoidal vessels in the bone marrow (BM), but the mecha-
nisms through which BM endothelial cells regulate HSC regenera-
tion remain unknown. We measured the function of BM ECs in
regulating hematopoietic regeneration after ionizing radiation by
deletion of the pro-apoptotic genes, Bak and Bax, within Tie21 cells
in Tie2Cre;Bak2/2;BaxFl/- mice. Following a lethal dose of total
body irradiation (TBI), these mice demonstrated protection of BM
HSCs and 100% survival, whereas mice that retained Bax expression
in Tie21 cells demonstrated depletion of BM HSCs and only 10%
survival (p\ 0.0001). Chimeric mice which lacked Bak and Bax in
BMHSCs but retained Bak and Bax in BMECs demonstrated an in-
termediate phenotype (42% survival), indicating that the intrinsic
pathway of apoptosis regulates HSC survival from radiation in an
HSC-autonomous manner and via an EC-dependent mechanism.
To determine the mechanism through which Tie21 BM ECs
regulate HSC regeneration, we generated primary BM EC lines
from Tie2Cre;Bak2/2;BaxFl/- mice (Bax2/2 BM ECs) and
Tie2Cre;Bak2/2;BaxFl/1 control mice (Bax1/- BM ECs). BM c-
kit1sca-11lin- (KSL) stem/progenitor cells were irradiated with
300 cGy and then placed in 7 day culture with Bax2/2 BM ECs or
Bax1/- BM ECs. Culture with Bax2/2 BM ECs yielded a 2000-fold
increased number of BM KSL cells (p\0.05) compared to cultures
with Bax1/- ECs. This significant expansion of phenotypic BM stem/
progenitor cells corresponded to a 4-fold increase in CFU-S12 cells
in the Bax2/2 EC cultures vs. Bax1/- EC cultures (p 5 0.01). Inter-
estingly, following TBI, mice bearing Bak and Bax deletion in BM
ECs displayed 18-fold increased concentration of epidermal growth
factor (EGF) in BM serum compared to control mice (p5 0.04), and
inhibition of EGF signaling blocked the ability of Bax2/2BMECs to
support the expansion of BM HSCs following irradiation compared
to culture with Bax2/2 ECs alone (p5 0.0002). Moreover, the addi-
tion of EGF to Bax1/- BM ECs culture compared to culture with
Bax1/- BM ECs alone significantly increased the recovery of BM
HSCs and progenitor cells following irradiation (p5 0.0004), which
was comparable to the recovery of BM HSCs and progenitor cells
observed in Bax2/2 BM EC cultures. These data demonstrate that
therapeutic protection of the BM vascular niche protects BM
HSCs from myelotoxic injury, and this protection is mediated by
EGF action on BM HSCs.SUPPORTIVE CARE
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Disseminated fungal infection causes significant morbidity and
mortality in children undergoing hematopoietic cell transplantation
(HCT). The widespread use of prophylactic oral triazoles has limi-
tations of poor absorption, interindividual variability in metabolism,
and hepatic toxicity. AmBisome (Amphotericin B liposomal com-
plex) has a better safety profile than the parent drug, produces higherplasma and tissue concentrations, but long-term use is limited by the
need for frequent intravenous administration. An alternative
approach to prophylaxis is once a week (wk) high-dose AmBisome
therapy.
Both animal and adult human data suggest that this dosing sched-
ule can be effective. We have previously shown that this dosing reg-
imen led to detectable and protective plasma levels of nonliposomal
amphotericin on the seventh day in pediatric HCT patients (Mehta
et al, 2006).
Here we report our clinical experience of use of weekly high-dose
(10mg/kg) AmBisome antifungal prophylaxis in high risk pediatric
patients undergoing HCT. A total of 25 infants and children with
various hematological and immune deficiency disorders undergoing
HCT are reviewed retrospectively. The median age was 1.5 years
(range 0.25-15).None of the patients had a history of previous fungal
infection. All patients had normal renal function prior to starting
weekly AmBisome and were on cyclosporine (CSA) for graft versus
host disease prophylaxis.
Total length of therapy expanded over 7 to 54 wks (median 16
wks). Results are described in Table. Majority of the patients toler-
ated AmBisome infusion well, except rash, hypertension, increased
work of breathing and hypotension in 2, 4, 1, and 1 patient respec-
tively. Renal dysfunction (increase in Cr to twice the baseline value),
was observed in 15 patients, at a median of 9 wks (range 1-31) of ther-
apy. Of note, 2 patients sustained significant renal dysfunction, with
Cr 4.9 and 5.1 (compared to baseline of 0.8 and 0.6 respectively) at
wk 10 and 7 respectively, in the setting of septic shock and receiving
gentamicin, vancomycin and CSA. None of the patients developed
breakthrough fungal infection during weekly AmBisome therapy.
Table 1. High-Dose Weekly AmBisome Antifungal Pro-
phylaxis: Results
Number or
Observations Median (Range)Total number of patients 25
Total weeks on AmBisome 16 (7-54)
Patients with infusional reactions 5
Patients with breakthrough fungal infection 0Number of patients with renal dysfunction (increase
in Cr to $ twice the baseline value)15- Time to development of renal dysfunction (weeks) 9 (1-31)
- Number of patients with reversal of renal
dysfunction to baseline
9- baseline creatinine 0.3 (0.3-0.8)
- highest creatinine 0.8 (0.3-5.1)
- end of therapy creatinine 0.5 (0.3-1.8)* Cr - creatinine
We conclude that, high dose weekly AmBisome prophylaxis is safe
and effective and provides a simple prophylaxis regimen that can
be administered for long periods to infants and children on an
outpatient basis. This approach has been used routinely at our
institution in the past several years with continued excellent
outcomes.
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MONITORING PLASMA VORICONAZOLE LEVELS MAY PREVENT SUB-
THERAPUTIC DOSING IN PEDIATRICS HEMATOPOEITIC STEM CELL
TRANSPLANTATION (HCT)
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Linda University Medical Center, Loma Linda, CA; 2Loma Linda
University Medical Center, Loma Linda, CA; 3Loma Linda University
Medical Center, Loma Linda, CA
Background: Voriconazole is frequently used for prophylaxis and
treatment of fungal infections during hematopoeitic stem cell trans-
plant (HCT). Clinical studies demonstrate a poorer outcome when
voriconazole concentrations are \ 0.5 mcg/ml. Pediatric dosing
schedules to achieve trough concentrations$ 0.5 mcg/ml are not es-
tablished and the recommended dose based on adult data is 4mg/kg/
dose q12h.
